中文摘要：

目的：探讨雄激素受体（AR）在不同雌激素受体（ER）状态乳腺癌中的表达与临床病理特征间的关系及预后。方法：从乳腺浸润性导管癌ER阳性和阴性病例中分别随机选取111例（ER＋组）与113例（ER一组），共计224例。采用免疫组化方法检测AR、ER、PR、HER-2、Ki-67、P53表达，对不同ER状态乳腺癌中AR表达与临床病理资料及预后因素进行分析。结果：AR在浸润性导管癌中的阳性表达率为67．9％（152／224），ER＋组和ER-组分别为80．2％（89／111）、55．8％（63／113）。ER＋组中AR的表达与肿瘤大小、组织学分级、pTNM分期和有无淋巴结转移相关（P〈0．05）；在ER-组中AR的表达与组织学分级、HER-2表达、绝经状态相关（P〈0．05）。单因素生存分析显示在ER＋组和ER-组AR阳性者均具有较好的预后（P〈0．001，P=0．046），Cox多因素回归分析显示在ER＋组AR表达可作为影响无瘤生存的独立因素。结论：AR可以作为指导临床内分泌治疗新的靶标，为不同ER状态乳腺癌激素治疗提供依据。

英文摘要：

Objective： To investigate the correlation between the expression of androgen receptor （ AR ） and the clinicopatholog- ic characteristics and prognosis of the breast invasive ductal carcinoma （ IDC ） of various estrogen receptor （ ER ） statuses. Methods： From January to December 2004, 111 cases from ER＋ cases and 113 cases from ER- cases were randomly allocated into two IDC groups： ER＋ group and ER- group. The protein expression ofAR, ER, PR, HER-2, Ki-67, and P53 from the 224 IDC cases were as- sayed using immunohistochemistry. The current study focused on the assessment of protein expressions in the groups （ ER＋/AR＋, ER＋/ AR-, ER-/AR＋, and ER-/AR- ） and their main characteristics. The prognostic differences in the cases of different AR and ER status were also evaluated. Results： The positive rate of AR was 67.9% （ 152/224 ）, and the rate of AR expression was 80.2% （ 89/111 ） and 55.8% （ 63/113 ） in the ER-positive and ER-negative cases, respectively. The AR expression in the ER-positive tumors was associated with tumor size, histological grade, pTNM, and endocrine therapy （ P 〈 0.05 ）. The AR expression in the ER-negative tumors was asso- ciated with the histological grade of the tumor, HER2 over-expression, and postmenopausal status （ P 〈 0.05 ）. The univariate analysis showed that the patients with AR-positive tumors in the ER＋ and ER- groups had significantly better disease-free survival than those with AR-negative tumors （ P 〈 0.001, P = 0.046 ）. The Cox regression analysis revealed that AR expression is an independent prognos- tic factor in the ER＋ group. Conclusion： AR is expressed in a great number of breast cancers of various ER status and it shows signifi- cant correlation with clinical hormone therapy and pathologic prognostic factors. Especially, AR plays a potential role in the clinical management of women patients with ER-negative breast cancer.